Rodriguez-Rodriguez S, Pomerantz A, Demichelis-Gomez R, Barrera-Lumbreras G, Barrales-Benitez O, Aguayo-Gonzalez A

Language: English
References: 19
Page: 171-175
PDF size: 116.15 Kb.

ABSTRACT

Background: The expression of HER2/neu in B-cell acute lymphoblastic leukemia has been reported in previous studies. Objective: The objective of this research was to study the expression of HER2/neu on the blasts of patients with acute leukemia from the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran. Methods: From June 2015 to February 2016, a HER2/neu monoclonal antibody was added to the panel of antibodies that we routinely use in patients with acute leukemia. An expression of ≥ 30% was considered positive. Results: We studied 33 patients: 19 had de novo leukemia (57.6%), three (9.1%) were in relapse, and in 11 (33.3%) their status could not be specified. Seventeen patients (51.5%) were classified as B-cell acute lymphoblastic leukemia with a median expression of HER2/neu of 0.3% (range 0-90.2). Three patients with B-cell acute lymphoblastic leukemia were positive for HER2/neu: 89.4%, 90.9%, and 62.4%. The first and third patient had de novo B-cell acute lymphoblastic leukemia. The second patient was in second relapse after allogeneic stem cell transplant. All three patients were categorized as high-risk at the time of diagnosis. Conclusions: In the studied Mexican population, we found a positive expression of HER2/neu in 17% of the B-cell acute lymphoblastic leukemia patients, similar to previous studies in which the expression was found in 15-50%.

REFERENCES

1. Sörensen J, Velikyan I, Sandberg D, et al. Measuring HER2-receptor expression in metastatic breast cancer using [68Ga] ABY-025 Affibody PET/CT. Theranostics. 2016;6:262-71.

2. Madani S-H, Rahmati A, Sadeghi E, et al. Survey of Her2-neu expression and its correlation with histology of gastric carcinoma and gastroesophageal junction adenocarcinoma. Asian Pacific J Cancer Prev. 2015;16:7755-8.

3. Zhu Y, Lu D, Lira ME, et al. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples. Exp Mol Pathol. 2015;100:287-93.

4. Kiba T, Morii N, Takahashi H, et al. Examination of the clinical efficacy of eribulin and trastuzumab in HER2-positive recurrent breast cancer. Mol Clin Oncol. 2016;4:47-50.

5. Wesoła M, Jelen M. A comparison of IHC and FISH cytogenetic methods in the evaluation of HER2 status in breast cancer. Adv Clin Exp Med. 2015;24:899-904.

6. Zhao Y, Dong X, Li R, Song J, Zhang D. Correlation between clinical-pathologic factors and long-term follow-up in young breast cancer patients. Transl Oncol. 2015;8:265-72.

7. Harris CA, Ward RL, Dobbins TA, Drew AK, Pearson S. The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. Ann Oncol. 2011;22:1308-17.

8. Yin W, Jiang Y, Shen Z, Shao Z, Lu J. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. PLoS One. 2011;6:1-9.

9. Cao Y, Marks JW, Liu Z, Cheung LH, Hittelman WN, Rosenblum MG. Design optimization and characterization of Her2/ neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies. Oncogene. 2014;33:429-39.

10. Torres S, Simmons C, Boileau J-F, McLeod D, Martins I, Trudeau M. Patterns in target-directed breast cancer research. Springerplus. 2016;5:1-15.

11. Bühring HJ, Sures I, Jallal B, et al. The receptor tyrosine kinase p185 HER2 is expressed on a subset of B-lymphoid blasts from patients with acute lymphoblastic leukemia and chronic myelogenous leukemia. Blood. 1995;85:1916-23.

12. Müller MR, Grünebach F, Kayser K, et al. Expression of Her-2/ neu on acute lymphoblastic leukemias: implications for the development of immunotherapeutic approaches. Clin Cancer Res. 2003;9:3448-53.

13. Chevallier P, Robillard N, Wuilleme-Toumi S, Méchinaud F, Harousseau JL, Avet-Loiseau H. Overexpression of Her2/neu is observed in one third of adult acute lymphoblastic leukemia patients and is associated with chemoresistance in these patients. Haematologica. 2004;89:1399-401.

14. Chevallier P, Robillard N, Houille G, et al. Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases. Leukemia. 2009;23:806-7.

15. Chevallier P, Robillard N, Charbonnier A, et al. Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study. Blood. 2012;119:2474-7.

16. Haen SP, Schmiedel BJ, Rothfelder K, et al. Prognostic relevance of HER2 / neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumab. Oncotarget. 2016;7:1-18.

17. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-48.

18. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in. J Clin Oncol. 2002;20:719-26.

19. Raetz EA, Cairo MS, Borowitz MJ, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: A children’s oncology group pilot study. J Clin Oncol. 2008;26:3756-62.